SOUTH SAN FRANCISCO, Calif., Nov. 7 /PRNewswire/ -- Trellis Bioscience, Inc., a privately held developer of innovative antibody-based products and technology that improves their discovery and production, today announced the election of Tony Scullion as chairman of the Trellis Board of Directors.
“Tony Scullion brings to our board over 30 years of broad strategic, operational and business development experience within the healthcare industry,” said Nolan Sigal, M.D., Ph.D., president of Trellis Bioscience. “His expertise and high level relationships within the pharmaceutical and biotechnology industry will serve Trellis well as we seek to expand our partnering efforts, both for application of our novel antibody screening technology to the programs of others and for collaborations aimed at advancing our own therapeutic antibody candidates. I believe our ability to recruit someone of Tony’s stature to our team is a strong endorsement of Trellis’ business model and value proposition.”
Tony Scullion is managing director, Investment Banking at Leerink Swann & Co. and previously served initially as chief executive officer and then as chairman of Memory Pharmaceuticals Corp. taking the company public in 2004 . Prior to that, he was head of Global Business Development at GlaxoWellcome plc and served on the Management Committee of that company. There Mr. Scullion was responsible for corporate in-licensing, out-licensing and alliances with divisional functions based in the United States and the United Kingdom. Prior to joining GlaxoWellcome, he spent 16 years with Pfizer Inc, where he held senior marketing, strategic and operational positions with assignments in the United Kingdom, Asia and the U.S. headquarters. Prior to Pfizer, he was with Hoechst Roussel. Mr. Scullion holds a B.Sc. in physiology and an M.Sc. in pharmacology from the University of London and is a member of the Chartered Institute of Marketing. He is also a member of the board of directors of Memory Pharmaceuticals, served previously on the board of Dynogen Pharmaceuticals and is a member of the board of directors of the Biotechnology Council of New Jersey (BCNJ).
About Trellis Bioscience, Inc.
Trellis Bioscience is a privately held company developing novel antibody therapeutics by leveraging innovative proprietary screening technology that addresses key bottlenecks in the discovery of high quality antibodies and the identification of high-secreting cell lines for their production. The company’s breakthrough technology, comprising proprietary nanoparticles, software algorithms and digital microscopy, achieves multiplexing and miniaturization in a qualitatively new format that enables detection of rare, favorable cells within a diverse population. This ability to characterize live cells in unprecedented detail leads to the discovery of better therapeutic antibodies or optimally secreting cell lines, and does so significantly faster than is achievable with other methods. Trellis currently is working with biopharmaceutical companies to discover and develop novel antibodies and recombinant proteins. Trellis is also generating its own pipeline of native human monoclonals, derived directly from human donors, which address unmet needs in infectious disease and oncology. For more information on Trellis Bioscience, Inc., please visit the company’s website at www.trellisbio.com.
Trellis Bioscience, Inc.
CONTACT: Nolan Sigal, M.D. Ph.D., President of Trellis Bioscience, Inc.,+1-650-616-1100; or Joan E. Kureczka of Kureczka/Martin Associates,+1-415-821-2413, or Jkureczka@comcast.net for Trellis Bioscience, Inc.
Web site: http://www.trellisbio.com/
